Global multi-stakeholder endorsement of the MAFLD definition

Global multi-stakeholder consensus on the redefinition of fatty liver disease

doi:10.1016/S2468-1253(22)00062-0

Global multi-stakeholder endorsement of the MAFLD definition

Global multi-stakeholder consensus on the redefinition of fatty liver disease

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	388-390
Number of pages	3
Journal	The Lancet Gastroenterology and Hepatology
Volume	7
Issue number	5
DOIs	https://doi.org/10.1016/S2468-1253(22)00062-0
Publication status	Published - May 2022

ASJC Scopus subject areas

Hepatology
Gastroenterology

Access to Document

10.1016/S2468-1253(22)00062-0

Cite this

@article{774389da71684b3b98bb1892e0a86365,

title = "Global multi-stakeholder endorsement of the MAFLD definition",

author = "{Global multi-stakeholder consensus on the redefinition of fatty liver disease} and Nahum M{\'e}ndez-S{\'a}nchez and Elisabetta Bugianesi and Gish, {Robert G.} and Frank Lammert and Herbert Tilg and Nguyen, {Mindie H.} and Sarin, {Shiv K.} and N{\'u}ria Fabrellas and Shira Zelber-Sagi and Fan, {Jian Gao} and Gamal Shiha and Giovanni Targher and Zheng, {Ming Hua} and Chan, {Wah Kheong} and Shlomo Vinker and Takumi Kawaguchi and Laurent Castera and Yusuf Yilmaz and Marko Korenjak and Spearman, {C. Wendy} and Mehmet Ungan and Melissa Palmer and Mortada El-Shabrawi and Gruss, {Hans Juergen} and Dufour, {Jean Fran{\c c}ois} and Anil Dhawan and Heiner Wedemeyer and Jacob George and Luca Valenti and Yasser Fouad and Manuel Romero‐Gomez and Mohammed Eslam and Abate, {Maria Lorena} and Bahaa Abbas and Abbassy, {Ahmed Amr} and {Abd El Ghany}, Waleed and {Abd Elkhalek}, Amira and {Abd ElMajeed}, Emad and Mohammad Abdalgaber and Alessio Aghemo and Anna Alisi and Massimo Colombo and Paola Dongiovanni and Mohamed Elgendy and Gianluigi Giannelli and Giannini, {Edoardo G.} and Federica Invernizzi and Min Li and Alessandra Mangia and Luca Miele",

note = "Funding Information: HW reports personal fees from Falk Foundation, Gore, Intercept, Pfizer, Merz, and Norgine; and grants from Merz and from Norgine, unrelated to this Correspondence. W-KC reports personal fees from Abbvie, Novo Nordisk, Boehringer Ingelheim, Viatris, and Hisky Medical, unrelated to this Correspondence. TK reports honorarium for lectures from Janssen Pharmaceutical KK, Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical, and EA Pharma, unrelated to this Correspondence. LC reports personal fees from Alexion, AbbVie, Echosens, Gilead, Intercept, Merck, Novo Nordisk, and Pfizer; and grants from Gilead, unrelated to this Correspondence. MHN reports grants from Glycotest, Gilead, Pfizer, Enanta, BK Kee Foundation, National Cancer Institute, and Vir Biotech; and personal fees from Spring Bank, Novartis, Janssen Eisai, Bayer, Intercept, Exact Science, Laboratory of Advanced Medicine, Helio, and Eli Lilly. MHN also reports acting as a consultant or on an advisory board for Gilead, unrelated to this Correspondence. LV reports grants from Gilead and personal fees from Viatris, unrelated to this Correspondence. RGG has received grants or research support in past 2 years from Gilead. RGG has also performed as a consultant or advisor in the past 2 years to Abbott, AbbVie, Altimunne, Antios, Arrowhead, Dynavax, Eiger, Eisai, Enyo, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, Helios, HepaTX, HepQuant, Intercept, Janssen, Merck, Pfizer, Topography Health, and Venatorx. RGG is on scientific or clinical advisory boards for AbbVie, Antios, Dynavax, Enyo, Genentech, Genlantis, Gilead, Helios, HepaTX, HepQuant, Intercept, Janssen, Merck, Pfizer, and Prodigy. RGG has performed as a consultant, advisor, or both to Topography Health. RGG is chair of the clinical advisory board for Prodigy. RGG is an advisory consultant for Fibronostics, Fujifilm–Wako, Perspectum, Quest, and Sonic Incytes. RGG is on data safety monitoring boards for Altimmune, Arrowhead, CymaBay Therapeutics, and Durect. RGG currently has consulting confidentiality agreements with AbbVie, Abbott, Access Biologicals, ADMA Biologics, AEC Partners, Aligos Therapeutics, Arena Pharmaceuticals, ArrowHead, Arterys, Alexion, Altimmune, Antios Therapeutics, AprosTx, Bayer, Cirina, Consumer Health Products Association, CymaBay Therapeutics, DiaSorin, Dova Pharmaceuticals, DRG Abacus, Durect, Dynavax, Echosens, Eiger, Enyp, Exelixis, Fibronostics, Forty-Seven, Fujifilm Wako Diagnostics, Gilead Sciences, HepQuant, HepaTx, IDLogiq, Intellia, Intercept, Inotek, Iqvia, Janssen–Johnson & Johnson, KannaLife, Laboratory for Advanced Medicine, Labyrinth, Life Line Screening, Eli Lilly, MedImmne, Merck, New Enterprise Associates, Ogilvy CommonHealth, Organovo, Patient Connect, Prodigy Biotech, Prometheus Laboratories, Refuah Solutions, Regulus Therapeutics, Salix, Shionogi, Spring Bank, and Trimaran. RGG has speaker's contracts to do promotional talks for AbbVie, Bristol Myers Squibb, Eisai, Gilead Sciences, and Intercept. RGG is a minor stock shareholder (only for projects in the liver field but not fatty liver disease-related areas) for RiboSciences and CoCrystal. RGG holds stock options in Eiger, Genlantis, HepQuant, and AngioCrine, unrelated to this Correspondence. All other authors declare no competing interests. ",

year = "2022",

month = may,

doi = "10.1016/S2468-1253(22)00062-0",

language = "English",

volume = "7",

pages = "388--390",

journal = "The Lancet Gastroenterology and Hepatology",

issn = "2468-1253",

publisher = "Elsevier Ltd",

number = "5",

}

TY - JOUR

T1 - Global multi-stakeholder endorsement of the MAFLD definition

AU - Global multi-stakeholder consensus on the redefinition of fatty liver disease

AU - Méndez-Sánchez, Nahum

AU - Bugianesi, Elisabetta

AU - Gish, Robert G.

AU - Lammert, Frank

AU - Tilg, Herbert

AU - Nguyen, Mindie H.

AU - Sarin, Shiv K.

AU - Fabrellas, Núria

AU - Zelber-Sagi, Shira

AU - Fan, Jian Gao

AU - Shiha, Gamal

AU - Targher, Giovanni

AU - Zheng, Ming Hua

AU - Chan, Wah Kheong

AU - Vinker, Shlomo

AU - Kawaguchi, Takumi

AU - Castera, Laurent

AU - Yilmaz, Yusuf

AU - Korenjak, Marko

AU - Spearman, C. Wendy

AU - Ungan, Mehmet

AU - Palmer, Melissa

AU - El-Shabrawi, Mortada

AU - Gruss, Hans Juergen

AU - Dufour, Jean François

AU - Dhawan, Anil

AU - Wedemeyer, Heiner

AU - George, Jacob

AU - Valenti, Luca

AU - Fouad, Yasser

AU - Romero‐Gomez, Manuel

AU - Eslam, Mohammed

AU - Abate, Maria Lorena

AU - Abbas, Bahaa

AU - Abbassy, Ahmed Amr

AU - Abd El Ghany, Waleed

AU - Abd Elkhalek, Amira

AU - Abd ElMajeed, Emad

AU - Abdalgaber, Mohammad

AU - Aghemo, Alessio

AU - Alisi, Anna

AU - Colombo, Massimo

AU - Dongiovanni, Paola

AU - Elgendy, Mohamed

AU - Giannelli, Gianluigi

AU - Giannini, Edoardo G.

AU - Invernizzi, Federica

AU - Li, Min

AU - Mangia, Alessandra

AU - Miele, Luca

N1 - Funding Information: HW reports personal fees from Falk Foundation, Gore, Intercept, Pfizer, Merz, and Norgine; and grants from Merz and from Norgine, unrelated to this Correspondence. W-KC reports personal fees from Abbvie, Novo Nordisk, Boehringer Ingelheim, Viatris, and Hisky Medical, unrelated to this Correspondence. TK reports honorarium for lectures from Janssen Pharmaceutical KK, Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical, and EA Pharma, unrelated to this Correspondence. LC reports personal fees from Alexion, AbbVie, Echosens, Gilead, Intercept, Merck, Novo Nordisk, and Pfizer; and grants from Gilead, unrelated to this Correspondence. MHN reports grants from Glycotest, Gilead, Pfizer, Enanta, BK Kee Foundation, National Cancer Institute, and Vir Biotech; and personal fees from Spring Bank, Novartis, Janssen Eisai, Bayer, Intercept, Exact Science, Laboratory of Advanced Medicine, Helio, and Eli Lilly. MHN also reports acting as a consultant or on an advisory board for Gilead, unrelated to this Correspondence. LV reports grants from Gilead and personal fees from Viatris, unrelated to this Correspondence. RGG has received grants or research support in past 2 years from Gilead. RGG has also performed as a consultant or advisor in the past 2 years to Abbott, AbbVie, Altimunne, Antios, Arrowhead, Dynavax, Eiger, Eisai, Enyo, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, Helios, HepaTX, HepQuant, Intercept, Janssen, Merck, Pfizer, Topography Health, and Venatorx. RGG is on scientific or clinical advisory boards for AbbVie, Antios, Dynavax, Enyo, Genentech, Genlantis, Gilead, Helios, HepaTX, HepQuant, Intercept, Janssen, Merck, Pfizer, and Prodigy. RGG has performed as a consultant, advisor, or both to Topography Health. RGG is chair of the clinical advisory board for Prodigy. RGG is an advisory consultant for Fibronostics, Fujifilm–Wako, Perspectum, Quest, and Sonic Incytes. RGG is on data safety monitoring boards for Altimmune, Arrowhead, CymaBay Therapeutics, and Durect. RGG currently has consulting confidentiality agreements with AbbVie, Abbott, Access Biologicals, ADMA Biologics, AEC Partners, Aligos Therapeutics, Arena Pharmaceuticals, ArrowHead, Arterys, Alexion, Altimmune, Antios Therapeutics, AprosTx, Bayer, Cirina, Consumer Health Products Association, CymaBay Therapeutics, DiaSorin, Dova Pharmaceuticals, DRG Abacus, Durect, Dynavax, Echosens, Eiger, Enyp, Exelixis, Fibronostics, Forty-Seven, Fujifilm Wako Diagnostics, Gilead Sciences, HepQuant, HepaTx, IDLogiq, Intellia, Intercept, Inotek, Iqvia, Janssen–Johnson & Johnson, KannaLife, Laboratory for Advanced Medicine, Labyrinth, Life Line Screening, Eli Lilly, MedImmne, Merck, New Enterprise Associates, Ogilvy CommonHealth, Organovo, Patient Connect, Prodigy Biotech, Prometheus Laboratories, Refuah Solutions, Regulus Therapeutics, Salix, Shionogi, Spring Bank, and Trimaran. RGG has speaker's contracts to do promotional talks for AbbVie, Bristol Myers Squibb, Eisai, Gilead Sciences, and Intercept. RGG is a minor stock shareholder (only for projects in the liver field but not fatty liver disease-related areas) for RiboSciences and CoCrystal. RGG holds stock options in Eiger, Genlantis, HepQuant, and AngioCrine, unrelated to this Correspondence. All other authors declare no competing interests.

PY - 2022/5

Y1 - 2022/5

UR - http://www.scopus.com/inward/record.url?scp=85127533180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85127533180&partnerID=8YFLogxK

U2 - 10.1016/S2468-1253(22)00062-0

DO - 10.1016/S2468-1253(22)00062-0

M3 - Letter

C2 - 35248211

AN - SCOPUS:85127533180

SN - 2468-1253

VL - 7

SP - 388

EP - 390

JO - The Lancet Gastroenterology and Hepatology

JF - The Lancet Gastroenterology and Hepatology

IS - 5

ER -

Global multi-stakeholder endorsement of the MAFLD definition

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this